Checked
Propanc Biopharma, Inc.
Nasdaq: PPCB · Pharmaceutical Preparations · Camberwell, Victoria, Australia
- Net income
- -$18.86M
- Total assets
- $12.78M
- Diluted EPS
- -$17.62
Company details
As reported to the SEC
- SEC CIK
- 1517681
- Stock
- Nasdaq: PPCB
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- Camberwell, Victoria, Australia
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- June 30
- Filer status
- Non-accelerated filer, Smaller reporting company
- Employer ID (EIN)
- 33-0662986
- Last annual report
- 09/25/2026
- Last quarterly report
- 05/14/2026
Formerly: Propanc Health Group Corp (until 04/05/2017)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 06/30/2026 | 06/30/2025 | 06/30/2024 | 06/30/2023 | 06/30/2022 |
|---|---|---|---|---|---|
| Operating income | -$18.19M | -$57.28M | -$1.54M | -$1.78M | -$1.99M |
| Net income | -$18.86M | -$58.92M | -$1.82M | -$2.66M | -$2.66M |
| Diluted earnings per share | -$17.62 | -$371.22 | -$1420.53 | -$1.80 | -$49.23 |
| Research and development | $625.5K | $223.7K | $248.1K | $247.9K | $256.1K |
| Total assets | $12.78M | $19.63M | $72.36K | $60.33K | $81.65K |
| Total liabilities | $3.38M | $5.73M | $3.85M | $3.18M | $3.11M |
| Shareholders' equity | $9.4M | $13.91M | -$3.78M | -$3.12M | -$3.02M |
| Cash and cash equivalents | $832K | $12.09K | $21.09K | $10.05K | $4.07K |
| Long-term debt | Not reported | $537.9K | $399.3K | $390.5K | $926.4K |
| Cash from operations | -$5.68M | -$405.2K | -$935.1K | -$1.11M | -$1.44M |
| Capital expenditures | $4.93K | Not reported | Not reported | Not reported | Not reported |
Recent filings
143 recent filings on record
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| DEF 14CSEC filing | 10/21/2026 | 10/20/2026 |
| PRE 14CSEC filing | 10/08/2026 | 10/08/2026 |
| S-1Registration statement (new securities) | 10/05/2026 | None |
| 10-KAnnual report | 09/25/2026 | 06/30/2026 |
| DEF 14CSEC filing | 08/21/2026 | 08/20/2026 |
| PRE 14CSEC filing | 08/05/2026 | 08/04/2026 |
| EFFECTNotice of effectiveness | 07/27/2026 | None |
| S-1Registration statement (new securities) | 07/17/2026 | None |
| 8-KDirector or officer change | 07/14/2026 | 07/08/2026 |
| 10-QQuarterly report | 05/14/2026 | 03/31/2026 |
| EFFECTNotice of effectiveness | 04/20/2026 | None |
| CORRESPLetter to the SEC staff | 04/16/2026 | None |
| UPLOADLetter from the SEC staff | 04/15/2026 | None |
| S-1Registration statement (new securities) | 04/10/2026 | None |
| DEF 14CSEC filing | 03/31/2026 | 03/31/2026 |
| PRE 14CSEC filing | 03/20/2026 | 03/19/2026 |
| PRE 14APreliminary proxy statement | 03/19/2026 | 03/19/2026 |
| 424B3Prospectus | 03/06/2026 | None |
| 8-KDirector or officer change | 02/26/2026 | 02/20/2026 |
| EFFECTNotice of effectiveness | 02/24/2026 | None |
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Propanc Biopharma, Inc.'s CIK number?
- Propanc Biopharma, Inc.'s SEC Central Index Key (CIK) is 1517681.
- What is Propanc Biopharma, Inc.'s stock ticker?
- Propanc Biopharma, Inc. trades as Nasdaq: PPCB.
- When does Propanc Biopharma, Inc.'s fiscal year end?
- Propanc Biopharma, Inc.'s fiscal year end on file with the SEC is June 30; its most recent fiscal year ended Jun 30, 2026.
- Where is Propanc Biopharma, Inc. headquartered?
- Propanc Biopharma, Inc.'s principal executive office on file with the SEC is in Camberwell, Victoria, Australia.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026